Efficacy and Safety of Mepolizumab in Eosinophilic COPD: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Key Points
To evaluate the efficacy and safety of mepolizumab in treating eosinophilic COPD.
Systematic review and meta-analysis of randomized controlled trials
Focused on the effects of mepolizumab on exacerbation rates and safety
Included data on symptom-free periods and adverse events
Mepolizumab reduced time to first moderate or severe exacerbation significantly (exact rates not provided)
Prolonged symptom-free periods were noted in treated individuals
No increase in adverse events reported compared to control
Abstract
Mepolizumab reduces the time to first moderate or severe exacerbation and prolongs symptom-free periods in patients with eosinophilic COPD, without increasing the risk of AEs.
AI에게 질문
Like
Bookmark
Share
AI에게 질문
Like
Bookmark
Share
Efficacy and Safety of Mepolizumab in Eosinophilic COPD: A Systematic Review and Meta-Analysis of Randomized Controlled Trials | Synapse